Sustained Clinical Benefit Seen for Pembrolizumab + Axitinib in Advanced Renal Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 8, 2025.

via HealthDay

FRIDAY, Aug. 8, 2025 -- For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib, according to a study published online Aug. 6 in Nature Medicine.

Brian I. Rini, M.D., from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and colleagues performed efficacy and prespecified exploratory biomarker analyses from the phase 3 KEYNOTE-426 trial, which included first-line pembrolizumab plus axitinib, with at least five years of follow-up to examine long-term durability of clinical outcomes for RCC.

The researchers found that compared with sunitinib, there were sustained benefits in overall survival (OS) and progression-free survival (PFS) with pembrolizumab plus axitinib (hazard ratios, 0.84 and 0.69, respectively); in addition, an increased objective response rate (ORR) was seen (60.6 versus 39.6 percent). Within the pembrolizumab plus axitinib arm, an 18-gene T-cell-inflamed gene expression profile was positively associated with OS, PFS, and ORR. Positive associations were seen for an angiogenesis signature with OS within the pembrolizumab plus axitinib arm and with OS, PFS, and ORR within the sunitinib arm. Within the pembrolizumab plus axitinib arm, the PBRM1 mutation had a positive association with ORR.

"There is an unmet need for biomarkers that are predictive of patient outcomes following treatment with available first-line therapies for advanced renal cell carcinoma," Rini said in a statement. "Although our analysis showed potential clinical utility of some RNA signatures in identifying patients who are likely to benefit the most from each treatment, further prospective clinical studies are needed."

Several authors disclosed ties to biopharmaceutical companies, including Merck, which manufactures pembrolizumab and funded the study.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-09 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords